A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

CLINICALTRIALS.GOV IDENTIFIER	RECRUITMENT STATUS	FIRST POSTED	LAST UPDATE POSTED
NCT03989414	RECRUITING	JUNE 18, 2019	OCTOBER 2, 2020

STUDY DESCRIPTION

Brief Summary

This is an open-label, multicenter, Phase 1/2 study to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Condition or Disease: Multiple Myeloma

Intervention/treatment: Drug: CC-92480
Drug: Bortezomib
Drug: Dexamethasone
Drug: Daratumumab
Drug: Carfilzomib

Phase: Phase 1/Phase 2

DETAILED DESCRIPTION

N/A

STUDY DESIGN

Study Type: Interventional

Estimated Enrollment : 384 participants

Intervention Model : Parallel Assignment

Masking: None (Open Label) ()

Primary Purpose: Treatment

Official Title: A Phase 1/2 Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Actual Study Start Date: September 2019

Estimated Primary Completion Date: September 2023

Estimated Study Completion Date: January 2025

ARMS AND INTERVENTIONS

Arm	Intervention/treatment
Experimental: CC-92480 in combination with bortezomib and dexamethasone Subjects in cohorts A, D and G will receive following: Oral CC-92480 at specified cohort dose administered over a 21-day cycle Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (>75 years old) administered over a 21-day cycle	Drug: CC-92480 CC-92480 Drug: Bortezomib Bortezomib Drug: Dexamethasone Dexamethasone
Experimental: CC-92480 in combination with carfilzomib and dexamethasone Subjects in cohort C and F will receive following: Oral CC-92480 at specified cohort dose administered over a 28-day cycle Intravenous (IV) carfilzomib 20 mg/m2 then 56 mg/m2 administered over a 28-day cycle Oral/IV dexamethasone 40 mg/day (20 mg/day for subjects >75 years old) administered over a 28-day cycle	Drug: CC-92480 CC-92480 Drug: Dexamethasone Dexamethasone Drug: Carfilzomib Carfilzomib
Experimental: CC-92480 in combination with daratumumab and dexamethasone Subjects in cohorts B and E will receive following: Oral CC-92480 at specified cohort dose administered over a 28-day cycle Intravenous (IV) daratumumab 16 mg/kg administered over a 28-day cycle Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle	Drug: CC-92480 CC-92480 Drug: Dexamethasone Dexamethasone Drug: Daratumumab Daratumumab

OUTCOME MEASURES

Primary Outcome Measures:
1. Overall response rate (ORR) [Time Frame: UP to approximately 3 years from enrollment]
Defined as the proportion of subjects who achieve partial response (PR)or better according to the International Myeloma Working Group (IMWG) Uniform Response Criteria .
2. Dose-limiting Toxicities (DLT) [Time Frame: UP to approximately 2 years from enrollment]
Number of participants with DLTs in the first cycle of the treatment
3. Adverse Events (AEs) [Time Frame: From first subject first visit until 28 days after the last subject discontinues study treatment.]
Type, frequency, seriousness and severity of adverse events (AEs), and relationship of AEs to study treatment

Secondary Outcome Measures:
1. Duration of response (DOR) [Time Frame: Up to approximately 3 years from enrollment]
Time from the first documentation of response (PR or greater) to the first documentation of progressive disease (PD) or death
2. Complete Response (CR) rate [Time Frame: Up to approximately 3 years from enrollment]
Percentage of subjects who achieved CR or better according to IMWG Uniform Response Criteria
3. Time-to-response (TTR) [Time Frame: UP to approximately 3 years from enrollment]
Time from first dose to the first documentation of response (PR or greater)
4. Very good partial response (VGPR) rate [Time Frame: Up to approximately 3 years from enrollment]
Percentage of subjects who achieved VGPR or better according to IMWG Uniform Response Criteria

---

ELIGIBILITY CRITERIA

Ages Eligible for Study: 18 Years and older (Adult, Older Adult)

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:
1. Subjects is ≥ 18 years of age and has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
2. Relapsed or refractory subjects must have measurable disease and have documented disease progression during or after their last anti-myeloma regimen.
3. Newly diagnosed subjects must have documented diagnosis with previously untreated symptomatic multiple myeloma.
4. Females of childbearing potential (FCBP) and male subjects must agree with the pregnancy prevention plan.

Exclusion Criteria:
1. Subject has a significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
2. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.

CONTACTS AND LOCATIONS

Contacts

Contact:

Locations

United States, Colorado	Colorado Blood Cancer Institute	Denver
United States, Florida	H. Lee Moffitt Cancer Center and Research Institute	Tampa
United States, Georgia	Winship Cancer Institute of Emory University	Atlanta
United States, Illinois	Northwestern University Feinberg School of Medicine	Chicago
United States, Illinois	University of Chicago Medicine	Chicago
United States, Massachusetts	Massachusetts General Hospital	Boston
United States, Massachusetts	Dana-Farber Cancer Institute	Boston
United States, Massachusetts	Beth Israel Deaconess Medical Center	Boston
United States, Michigan	Barbara Ann Karmanos Cancer Center	Detroit
United States, Minnesota	Mayo Clinic	Rochester
United States, New Jersey	Hackensack University Medical Center	Hackensack
United States, North Carolina	Wake Forest University Baptist Medical Center	Winston-Salem
United States, Ohio	The Ohio State University Comprehensive Cancer Center	Columbus
United States, Tennessee	Sarah Cannon Cancer Center	Nashville
United States, Texas	The University of Texas - MD Anderson Cancer Center	Houston
United States, Washington	Swedish Cancer Institute	Seattle
Canada, Alberta	Tom Baker Cancer Center	Calgary
Canada, Alberta	University of Alberta - Faculty of Medicine and Dentistry	Edmonton
Canada, Nova Scotia	Queen Elizabeth II Health Sciences Centre	Halifax
Canada, Ontario	Princess Margaret Cancer Centre	Toronto

Canada, Quebec	Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal	Montreal
Czechia	Fakultni Nemocnice Brno	Brno
Czechia	Fakultni Nemocnice Ostrava	Ostrava-Poruba
Czechia	Charles University General Hospital	Praha 2
Denmark	Rigshospitalet University Hospital	Copenhagen
Denmark	Odense University Hospital	Odense
Denmark	Vejle Hospital	Vejle
France	Hopital Claude Huriez CHRU Lille	Lille cedex
France	Institut Paoli Calmette Hematologie	Marseille cedex
France	Hotel Dieu CHU Nantes	Nantes Cedex 01
France	Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole	Toulouse Cedex 9
France	CHRU Hopital Bretonneau	Tours cedex
Germany	Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik	Freiburg
Germany	Universitaetsklinikum Hamburg-Eppendorf	Hamburg
Germany	Universitaetsklinikum Heidelberg	Heidelberg
Germany	Klinikum rechts der Isar der Technischen Universitaet Muenchen	Munchen
Germany	Universitaets-klinikum Wuerzburg	Wuerzburg
Greece	Alexandra General Hospital of Athens	Athens
Italy	ASST Spedali Civili P.O. di Brescia	Brescia
Italy	Fondazione IRCCS Istituto Nazionale dei Tumori	Milan
Italy	Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova	Reggio Emilia
Italy	Azienda Ospedaliera Citta della Salute e della Scienza di Torino	Torino
Spain	Hopsital Germans Trias I Pujol	Badalona
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Clinica Universidad de Navarra	Pamplona
Spain	Universitario de Salamanca - Hospital Clinico	Salamanca
Spain	Hospital Universtario Marques de Valdecilla	Santander

Sponsors and Collaborators

Celgene

Investigator

Study Director : Tsvetan Biyukov, MD Bristol-Myers Squibb

MORE INFORMATION

Responsible Party :	Celgene
ClinicalTrials.gov Identifier :	NCT03989414
Other Study ID Numbers :	CC-92480-MM-002, U1111-1233-5619, 2018-004767-31
First Posted :	June 18, 2019
Last Update Posted :	October 2, 2020
Last Verified :	September 2020
Individual Participant Data (IPD) Sharing Statement:	
Plan to Share IPD:	Yes
Plan Description:	Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
Supporting Materials:	Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report (CSR), Analytic Code
Time Frame:	See Plan Description

Access Criteria:	See Plan Description
URL:	https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No
Keywords provided by Celgene:	*CC-92480* *Relapsed or Refractory Multiple Myeloma Newly Diagnosed Multiple Myeloma* *Multiple Myeloma*
Additional relevant MeSH terms :	*Multiple Myeloma* *Neoplasms, Plasma Cell*